{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:09:17Z","timestamp":1784812157073,"version":"3.55.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.2967\/jnumed.124.268695","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:20:21Z","timestamp":1738254021000},"page":"385-390","source":"Crossref","is-referenced-by-count":6,"title":["DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of<sup>177<\/sup>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma"],"prefix":"10.2967","volume":"66","author":[{"given":"Cameron N.","family":"Johnstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Osellame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid J.G.","family":"Burvenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia N.","family":"Ivashkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Wheatcroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin B.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank T.","family":"Zenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sirrenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025030410451232000_66.3.385.1","first-page":"443","article-title":"A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route","volume":"11","author":"Chakravarty","year":"2021","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2025030410451232000_66.3.385.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2008.05.002"},{"key":"2025030410451232000_66.3.385.3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde.14.6","article-title":"Uptake, internalization and nuclear translocation of radioimmunotherapeutic agents","volume":"5","author":"Hillyar","year":"2014","journal-title":"Ther Deliv."},{"key":"2025030410451232000_66.3.385.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025030410451232000_66.3.385.5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2025030410451232000_66.3.385.6","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.48"},{"key":"2025030410451232000_66.3.385.7","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.TM118.000371"},{"key":"2025030410451232000_66.3.385.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2008.06.018"},{"key":"2025030410451232000_66.3.385.9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0734"},{"key":"2025030410451232000_66.3.385.10","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1016\/j.apsb.2021.07.029","article-title":"DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm Sin B."},{"key":"2025030410451232000_66.3.385.11","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.7150\/thno.82963","article-title":"DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Reuvers","year":"2023","journal-title":"Theranostics."},{"key":"2025030410451232000_66.3.385.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01151-6"},{"key":"2025030410451232000_66.3.385.13","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3390\/cancers14061392","article-title":"Carbonic anhydrase IX: a renewed target for cancer immunotherapy","volume":"14","author":"Campos","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025030410451232000_66.3.385.14","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res."},{"key":"2025030410451232000_66.3.385.15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3390\/cancers14061454","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"14","author":"Parakh","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025030410451232000_66.3.385.16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40291-024-00699-w","article-title":"Lutetium-177 labelled anti-PSMA monoclonal antibody (Lu-TLX591) therapy for metastatic prostate cancer: treatment toxicity and outcomes","volume":"28","author":"Nguyen","year":"2024","journal-title":"Mol Diagn Ther."},{"key":"2025030410451232000_66.3.385.17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur Urol."},{"key":"2025030410451232000_66.3.385.18","doi-asserted-by":"publisher","DOI":"10.2310\/7290.2014.00031"},{"key":"2025030410451232000_66.3.385.19","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer."},{"key":"2025030410451232000_66.3.385.20","first-page":"13","article-title":"A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma","volume":"7","author":"Davis","year":"2007","journal-title":"Cancer Immun."},{"key":"2025030410451232000_66.3.385.21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00113"},{"key":"2025030410451232000_66.3.385.22","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1039\/D3SC06365H","article-title":"Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX","volume":"15","author":"Morgan","year":"2024","journal-title":"Chem Sci."},{"key":"2025030410451232000_66.3.385.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266894"},{"key":"2025030410451232000_66.3.385.24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz694%J"},{"key":"2025030410451232000_66.3.385.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0114-z"},{"key":"2025030410451232000_66.3.385.26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2025030410451232000_66.3.385.27","doi-asserted-by":"crossref","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol."},{"key":"2025030410451232000_66.3.385.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.026"},{"key":"2025030410451232000_66.3.385.29","doi-asserted-by":"crossref","first-page":"e0172276","DOI":"10.1371\/journal.pone.0172276","article-title":"The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images","volume":"12","author":"Zhan","year":"2017","journal-title":"PLoS One."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:47:22Z","timestamp":1741114042000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.2967\/jnumed.124.268695"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268695","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}